Thursday | June 25, 2020
BioLinks

Welcome to our newly formatted LifeSciences BC newsletter!

With the support and valuable contribution from Coast Communications we decided it was time for a redo of our weekly newsletter. We hope you enjoy the updated content and as always, would love to hear from you! Please share your life science news with us by sending it to sogilvie@lifesciencesbc.ca .
LSBC Upcoming Events
“Update on the fight against COVID-19”

  • KEYNOTE: Dr. Mel Krajden, Medical Director – BCCDC Public Health Laboratory, Medical Head, Hepatitis – BCCDC, Professor – UBC

  • Dr. Brad Nelson, Co-Founder & CEO, Innovakine Therapeutics Inc.

Platinum Sponsors
LSBC Member News
Minister Bains announces members of new Industry Strategy Council
June 2, 2020 – Ottawa, Ontario The Government of Canada recognizes that a smooth economic recovery will require continued collaboration between the public and private sectors in the wake of the direct effects, changes and adaptations related to COVID-19. READ MORE
I MC responds to the release of revised PMPRB guidelines
Ottawa, June 19, 2020 – Innovative Medicines Canada released the following statement today in response to the release of revised PMPRB pricing guidelines: “We have just received the revised Guidelines and we will be examining them closely, in consultation with our members, after which we will be in a position to comment in more detail. READ MORE
CALL TO ACTION – COVID 19 ALL BC MEDICAL SUPPLIERS, LABORATORIES AND SERVICE PROVIDERS
June 22, 2020 – Vancouver, B.C. – As COVID-19 places a strain on urgent patient care and therapeutic treatments, a critical need has developed for medical supplies and services that are indispensable on the front line. READ MORE
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
Vancouver, BC – June 19, 2020 A clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission... READ MORE
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II
SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de Novo protein therapeutics, today announced.... READ MORE
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
SAN DIEGO, June 22, 2020 /PRNewswire/ —  DelMar Pharmaceuticals, Inc.  (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM)  READ MORE
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced it has completed enrollment for the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome  READ MORE
Building Canada’s Leadership Talent Amidst a COVID World -- One Week Left To Apply To AdMare’s 2020-2021 Executive Institute
June 23, 2020 – adMare BioInnovations, Canada’s global life sciences venture, is proud to continue to build on its highly-successful Executive Institute, a 10-month, highly-focused executive development program custom– designed to grow the management talent needed for Canadian life sciences to lead the world — and is now accepting applications to its 2020-2021 cohort. Deadline to apply: June 30th, 2020 READ MORE
DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
SAN DIEGO, June 24, 2020 /PRNewswire/ —  DelMar Pharmaceuticals, Inc.  (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today it has received a $500,000 loan from the National Brain Tumor Society (NBTS) and the National Foundation for Cancer Research.... READ MORE
InMed Introduces IntegraSynTM: An Integrated Cannabinoid Manufacturing System
Vancouver, BC – June 24, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”)... READ MORE
Gold Sponsors
LSBC Member Spotlight
Presenting LifeSciences BC's Newest Members
LifeSciences BC would like to welcome Alpha 9 Therapeutics and Kardium as our newest members this week!


Community - Sector Interest
Deloitte’s FAST 50 Program - Sponsored by RBC
Enterprise 15 – Open to companies with a minimum revenue of $10 million in 2016 and a minimum revenue of $25 million in 2019
We Want to Hear from You!

The COVID-19 pandemic has challenged and changed our province. Across B.C., we have been touched by job loss and change, health concerns, worries about how our families and communities can cope, and increasing uncertainty about the future. Read More
Canada may be losing its status as a top global destination for new medicine launches
TORONTO, June 25, 2020 /CNW/ - Canada has long been considered a top global jurisdiction for new medicine launches. However, a new report published by Life Sciences Ontario (LSO) shows that new medicine launches in Canada fell dramatically in 2019. READ MORE
Repare soars to largest ever IPO of a Canadian biotech firm in Nasdaq debut
June 22, 2020 - Globe & Mail - Montreal cancer drug developer Repare Therapeutics Inc. joined the ranks of US$1-billion Canadian drug developers Friday... READ MORE
Silver Sponsors
LSBC Job Board
Bronze Sponsors
Posting A JOB on the LSBC Website
Did you know  LifeSciences BC's Job Board  gets approximately 60,000 visitors a month?

LSBC Membership Discounts on Job Postings
 
As an LSBC member, your first five job postings EARNS a free repost on Biotalent Canada's  The Petri Dish ? After your first five reposts, you will also receive 25% off all job postings on  The Petri Dish . Want more info? 

Please contact Sue Callaghan: talent@lifesciencesbc.ca